Yan Leyfman: Analyzing Demographic Trends in NCI-Sponsored Early-Phase Cancer Clinical Trials
Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about recent paper by Maria Farooq et al., published in Cancer Discovery.
“New study led by Dr. Elad Sharon (Dana-Farber Cancer Institute) analyzes demographic trends in NCI-sponsored early-phase cancer clinical trials (2000–2023):
Enrollment rose among:
Adults aged 65–74 (24.6% → 32.3%)
Adults aged 75–84 (6.2% → 12.4%)
Hispanic/Latino (4.5% → 7.7%)
Asian/Pacific Islander (2.2% → 4.4%)
Non-Hispanic Black patients (6.1% → 7.2%)
But gaps persist:
Hispanic/Latino and Black participation still trails cancer incidence
American Indian and Alaska Native participation remains negligible
Key inflection point:
The 2014 launch of the Experimental Therapeutics Clinical Trials Network led to:
Improved demographic representation
Shorter distances between patients and enrolling institutions
Progress, but disparities remain. A critical reminder of the work ahead in trial equity.”
Title: Demographic Trends in NCI-Sponsored Early Phase Clinical trials (2000–2023): A Cohort Study
Authors: Maria Farooq, Elad Sharon, Naoko Takebe
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023